Bellicum Pharmaceuticals, which is developing adjunct cancer immunotherapies based on a conditionally responsive platform, filed on Tuesday with the SEC to raise up to $115 million in an initial public offering.
2014 has seen a rush of biotech IPOs, and several are developing cancer immunotherapies. These include Kite Pharma (KITE), Affimed Therapeutics (AFMD), Immune Design (IMDZ) and Argos Therapeutics (ARGS). Juno Therapeutics (JUNO), which is developing immunotherapies for lymphomas, leukemias and other cancers, filed for a $150 million IPO on Monday.
The Houston, TX-based company, which was founded in 2004, plans to list on the NASDAQ under the symbol BLCM. Bellicum initially filed confidentially on October 17, 2014. Jefferies, Citi and Piper Jaffray are the joint bookrunners on the deal. No pricing terms were disclosed.
